In Figure 3, we report all the antibodies that showed at least 10 percentage units higher reactivity either in anti-MPO positive or anti-PR3 positive AAV patients, as well as for the anti-MPA vs anti-GPA comparison and the anti-MPO positive MPA patients vs anti-PR3 positive GPA patients’ comparison. This evidence concerns the gene GYPA and microscopic polyangiitis.